Retinal Detachment RhegmatogenousCohort-NHSNCT07386678
Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment
An observational study of Retinal Detachment Rhegmatogenous and Proliferative Vitreoretinopathy, run by University College, London at 1 site in United Kingdom.
Trial summary
Disease or general study area: Uncomplicated rhegmatogenous retinal detachment (RRD) and risk of proliferative vittroretinopathy (PVR) Purpose and nature of the study: 1. Characterise the cytokine profile of vitreous fluid in uncomplicated RRD. 2. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Retinal Detachment Rhegmatogenous, Proliferative Vitreoretinopathy, Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment
- How many people
- 50 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 27 Apr 2026to 27 Jan 2027
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: * Adults ≥18 years * Uncomplicated primary rhegmatogenous retinal detachment * Moorfields Eye Hospital
Who may be able to join
- Adults ≥18 years
- Uncomplicated primary rhegmatogenous retinal detachment
- PVD present
- No PVR-A/B/C
- Phakic or pseudophakic.
Who cannot join
- Patients <18 years
- Patients lacking capacity
- Previous vitrectomy
- Previous cryopexy
- Aphakia
- No fundal view
Show all 12Show fewer
- Diabetic retinopathy of any severity
- Retinal detachment secondary to infective causes e.g. acute retinal necrosis, toxoplasmosis scars
- Retinal detachment secondary to congenital defects e.g. optic disc pit/coloboma
- Exudative retinal detachment
- Tractional retinal detachment
- Ongoing involvement in another ocular trial.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United Kingdom1 site
Moorfields Eye Hospital
London, N17 9GZ
Achini K, 07951650070, a.makuloluwa@nhs.net
James Bainbridge, j.bainbridge@ucl.ac.uk
About this study
Disease or general study area: Uncomplicated rhegmatogenous retinal detachment (RRD) and risk of proliferative vittroretinopathy (PVR)
Purpose and nature of the study:
Read more
- Characterise the cytokine profile of vitreous fluid in uncomplicated RRD.
- Develop a risk model to predict development of PVR after retinal detachment surgery using imaging and molecular biomarkers.
- To develop deep learning/artificial intelligence (AI) models for PVR detection in retinal detachment.
Inclusion criteria:
50 adult ( ≥18 years) patients with uncomplicated rhegmatogenous retinal detachments without PVR.
What participating will involve:
Pre- and post-operative assessments and intervention will follow standard of care for patients with rhegmatogenous retinal detachments.
Additional intervention will include non-invasive imaging of anterior chamber flare, vitreous, wide-field retina, macula optical coherence tomography (OCT) and macula OCT-angiography (OCT-A) as well as, seeking participant's consent on collecting their vitreous fluid at time of their surgery for cytokine analysis.
Read the detailed description
This is an observational cohort study of 50 participants with uncomplicated rhegmatogenous retinal detachment. Participants will have their vitreous fluid collected at the time of surgery for cross-sectional analysis of cytokine milieu and a series of pre-operative and post-operative non-invasive imaging over 3 months. Unfortunately, 15-20% of the patients with primary retinal detachment will have recurrent retinal detachments following surgery secondary to an anomalous scarring process called proliferative vitreoretinopathy (PVR).
Therefore, aims of this study are to:
- Characterise the cytokine profile of vitreous fluid in uncomplicated RRD.
- Develop a risk model to predict development of PVR after retinal detachment surgery using imaging and molecular biomarkers.
- To develop deep learning/artificial intelligence (AI) models for PVR detection in retinal detachment.
Above will guide future treatments for PVR and further identify high risk populations not just from a clinical perspective but with the utilisation of their imaging and molecular biomarkers.
- Conditions
- Retinal Detachment Rhegmatogenous, Proliferative Vitreoretinopathy, Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment
- Keywords
- Cytokines, Imaging
- Medical subject headings
- Vitreoretinopathy, Proliferative
What is being measured
The primary outcome is the main question the study is designed to answer.
Characterise the cytokine milieu in an uncomplicated RRD eye.
Study cytokine profile using a multiplex assay that includes all relevant cytokines.
Measured: 3 months
Secondary outcomes (2)
Develop a risk model for development of PVR after retinal detachment surgery using imaging and molecular biomarkers.
Study demographics, existing and novel risk factors from imaging aqueous, vitreous, retinal vasculature and retinal structure, and cytokine molecular biology. Use a risk model for risk-stratification of patients who develop PVR re detachment.
Measured: 3 months
To develop deep learning AI models for PVR detection in retinal detachment.
Using ultra-widefield retinal imaging and optical coherence tomography in human retinal detachment models.
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Feb 2026
- Study start27 Apr 2026 (estimated)
- Primary completion27 Jan 2027 (estimated)
- Study completion27 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Retinal Detachment RhegmatogenousStudies of the same condition, open and under way.
- More trials run by University College, LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- University College, London
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07386678
- Sponsor's protocol ID
- EDGE 179423
- Acronym
- Cohort-NHS
- Status last verified
- Jan 2026
- First submitted
- 27 Jan 2026
- Last updated
- 6 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Cytokine profile
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of Imaging and Molecular Biomarkers in Uncomplicated Rhegmatogenous Retinal Detachment
- ClinicalTrials.gov ID
- NCT07386678
- Acronym / sponsor ID
- Cohort-NHS / EDGE 179423
- Conditions
- Retinal Detachment Rhegmatogenous, Proliferative Vitreoretinopathy, Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment
- Keywords
- Cytokines, Imaging
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- University College, LondonUniversity, hospital or other
- Study start
- 27 Apr 2026 (estimated)
- Primary completion
- 27 Jan 2027 (estimated)
- Study completion
- 27 Jan 2027 (estimated)
- First posted
- 4 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Disease or general study area: Uncomplicated rhegmatogenous retinal detachment (RRD) and risk of proliferative vittroretinopathy (PVR)
Purpose and nature of the study:
- Characterise the cytokine profile of vitreous fluid in uncomplicated RRD.
- Develop a risk model to predict development of PVR after retinal detachment surgery using imaging and molecular biomarkers.
- To develop deep learning/artificial intelligence (AI) models for PVR detection in retinal detachment.
Inclusion criteria:
50 adult ( ≥18 years) patients with uncomplicated rhegmatogenous retinal detachments without PVR.
What participating will involve:
Pre- and post-operative assessments and intervention will follow standard of care for patients with rhegmatogenous retinal detachments.
Additional intervention will include non-invasive imaging of anterior chamber flare, vitreous, wide-field retina, macula optical coherence tomography (OCT) and macula OCT-angiography (OCT-A) as well as, seeking participant's consent on collecting their vitreous fluid at time of their surgery for cytokine analysis.
Detailed description
This is an observational cohort study of 50 participants with uncomplicated rhegmatogenous retinal detachment. Participants will have their vitreous fluid collected at the time of surgery for cross-sectional analysis of cytokine milieu and a series of pre-operative and post-operative non-invasive imaging over 3 months. Unfortunately, 15-20% of the patients with primary retinal detachment will have recurrent retinal detachments following surgery secondary to an anomalous scarring process called proliferative vitreoretinopathy (PVR).
Therefore, aims of this study are to:
- Characterise the cytokine profile of vitreous fluid in uncomplicated RRD.
- Develop a risk model to predict development of PVR after retinal detachment surgery using imaging and molecular biomarkers.
- To develop deep learning/artificial intelligence (AI) models for PVR detection in retinal detachment.
Above will guide future treatments for PVR and further identify high risk populations not just from a clinical perspective but with the utilisation of their imaging and molecular biomarkers.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Months
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- * Adults ≥18 years * Uncomplicated primary rhegmatogenous retinal detachment * Moorfields Eye Hospital
Key inclusion criteria (5 listed)
- Adults ≥18 years
- Uncomplicated primary rhegmatogenous retinal detachment
- PVD present
- No PVR-A/B/C
- Phakic or pseudophakic.
Key exclusion criteria (12 listed)
- Patients <18 years
- Patients lacking capacity
- Previous vitrectomy
- Previous cryopexy
- Aphakia
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Characterise the cytokine milieu in an uncomplicated RRD eye.
Time frame: 3 months
Study cytokine profile using a multiplex assay that includes all relevant cytokines.
2 secondary outcomes
Develop a risk model for development of PVR after retinal detachment surgery using imaging and molecular biomarkers.
Time frame: 3 months
To develop deep learning AI models for PVR detection in retinal detachment.
Time frame: 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2026.
- Individual participant dataSharing planned: Yes. Cytokine profile
Related trials for Retinal Detachment Rhegmatogenous
RecruitingPhase 2
Prevention of ProliFerative Vitreoretinopathy With Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment
RecruitingPhase 3
Treatment of Retinal Detachment in People Who Have Not Had Cataract Surgery With Vitrectomy vs Vitrectomy and Cataract Removal
Rhegmatogenous Retinal Detachment
Active, not recruiting
Ocular Hypotony and Refractive Predictability in RRD Surgery
Rhegmatogenous Retinal Detachment, Hypotony Ocular
RecruitingPhase 1/2
Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Not yet recruitingPhase 1
The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy
Proliferative Vitreoretinopathy, Proliferative Vitreo-Retinopathy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Retinal Detachment Rhegmatogenous and Proliferative Vitreoretinopathy, run by University College, London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 6 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Characterise the cytokine milieu in an uncomplicated RRD eye. (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2026.